Did you know that SGLT2 blockade can reduce progression to ESKD by at least a decade in patients with mild-to-moderately decreased eGFR?

Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/990093?ecd=bdc_podcast_libsyn_mscpedu